(Date:12/2/2008)...EAK to collect and disseminate pharmacy experience...ue, Wash. (PRWEB) December 2, 2008 -- Pharmacy On... initiative to focus public and industry attention...ck-off of SPEAK will occur during the American Soc...ear Clinical Meeting, to be held December 7-11 in ...
(Date:12/2/2008)... this year,s ASHP midyear meeting, FFF Enterprises...r of critical-care biopharmaceuticals and vaccines...chain integrity and demonstrate how the company ha.... (Booth #1439) , (Vocus)...eeting, FFF Enterprises, the nation,s largest and ...
(Date:12/2/2008)... the International Day of Disabled Persons is reco...story of a young boy born with backwards pointing ...y, a floating hospital docked in Liberia, Benedict...with the other children his age. High resolution...hipsnewsroom.org , Garde...
(Date:12/2/2008)...ar Unafraid: Learning to Trust No Matter What by J...2008 Awards.,In 1977, strange symptoms assaulted ... with multiple sclerosis. Jo had backpacked up 14,...ty miles an hour. , Battl...raid: Learning to Trust No Matter What by Jo Franz...
Breaking Medicine News(10 mins):Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2Health News:FFF Enterprises Unveils ‘The 8 Critical Steps to Guaranteed Channel Integrity' at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Orlando 2Health News:FFF Enterprises Unveils ‘The 8 Critical Steps to Guaranteed Channel Integrity' at the American Society of Health-System Pharmacists (ASHP) Midyear Meeting in Orlando 3Health News:Mercy Ships Recognizes International Day of Disabled Persons 2Health News:Mercy Ships Recognizes International Day of Disabled Persons 3Health News:Nothing Has Stopped This Woman--MS, Divorce, Abuse, Trauma--How to Live Adventurously and Fearlessly No Matter What Happens 2Health News:Nothing Has Stopped This Woman--MS, Divorce, Abuse, Trauma--How to Live Adventurously and Fearlessly No Matter What Happens 3(Date:11/25/2008)...Nov. 25 Proteolix, Inc., a,leader...utics that target,protein degradation pathways in...that data from two ongoing Phase 2 clinical trials...nted at the upcoming 50th Annual Meeting of the,A...is the first in a new class,of specific proteasom...
(Date:11/25/2008)...ical Trial to Assess Survival of Patients Receivin...ectable Hepatocellular Carcinoma , , BELLEV...Oncology, Inc. (LSO) today announced the completio... of Light Infusion Therapy(TM) (Litx(TM)) as a tre...HCC), also known as hepatoma or primary liver canc...
(Date:11/24/2008)...Newswire/ -- Domino,s Pizza (NYSE: DPZ ), the,r...ng up to raise dough for,the kids of St. Jude Chi...,Thanks and Giving campaign. Domino,s customers wi...nt of purchase to benefit the children of St. Jude...one or when ordering online at, www.dominos.com ....
(Date:11/24/2008)...ion leadership and long-term commitment to hepatit...PRNewswire-FirstCall/ -- Schering-Plough Corporati... on boceprevir, its lead investigational oral hepa...development. The company believes boceprevir has ...lass protease inhibitor for treating chronic hepat...
Breaking Medicine Technology:Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 24151 1Gene Mutation Puts Some Kids at Risk for Tobacco Addiction 24151 2U S Health Care Still Ill Survey Finds 24149 1U S Health Care Still Ill Survey Finds 24149 2U S Health Care Still Ill Survey Finds 24149 3Aethons Train Themed Delivery Robot Available To Childrens Hospitals Nationwide 24147 1Aethons Train Themed Delivery Robot Available To Childrens Hospitals Nationwide 24147 2WeissComm Partners Ranks Among Top 5 Best U S Midsize PR Agencies to Work For 24145 1WeissComm Partners Ranks Among Top 5 Best U S Midsize PR Agencies to Work For 24145 2...reatment data from,Synovate Healthcare’s Eur...east cancer patients in the UK could become eligib...th rates in,patients. The treatment was the subjec... of The Lancet (12 February 2007). Lower,mortality...the,aromotase inhibitor, Aromasin (exemestane), af...
...l of Cell Science Shows ONCONASE Uptake in,Cells D...05, 2007 /PRNewswire-FirstCall/ --,Alfacell Corpor...ve,identified the pathway that ONCONASE (ranpirnas...nal of Cell Science (2007; 120: 1405-1411),a pape...Girona in,Spain and the University of Montpellier ...
Other Medicine Technology:Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor 2Over 10,000 UK Breast Cancer Patients Could Become Eligible Within,the Next Year for a Breast Cancer Therapy Showing Increased,Survival Rates, Reveals Synovate Healthcare’s European,Oncology Monitor 3Researchers Identify Intracellular Pathway of Alfacell's Onconase 2Researchers Identify Intracellular Pathway of Alfacell's Onconase 3...ased, 2-8-channel system for measuring bioelectric...optic nerve. The basic set comprises: computer dev...ioelectrical amplifier, electrodes and checkerboar...o install. The recorded curves are displayed on a ...
A sophisticated research tool that allows to see the fundus picture of the area which is being stimulated. Besides it also includes the refractive pupil camera enabling the examiner to switch between
5 mm
Cannula and irrigation extension. Overall Length 150 mm (6.25"). Light Curve.
Medicine Products: